Written Authority Required Drugs 012-63060000

Term

Description

Condition > IVR # > IVR program

abatacept

Section 85 and Section 100 listed pharmaceutical benefit.

Public and private hospital authority required -
(Section 100 only).

• rheumatoid arthritis > IVR 2 > IVR B

adalimumab

Description

Section 85 and Section 100 listed pharmaceutical benefit.

Public and private hospital authority required -
(Section 100 only).

• ankylosing spondylitis > IVR 2 > IVR B
• Crohn's disease - adult and paediatric > IVR 6 > IVR B
• enthesitis/spondylitis juvenile idiopathic arthritis > IVR 2 > IVR B
• fistulising Crohn's disease > IVR 6 > IVR B
• hidradenitis suppurativa > IVR 5 > IVR A
• juvenile idiopathic arthritis > IVR 2 > IVR B
• non-infectious uveitis > IVR 2 > IVR B
• psoriatic arthritis > IVR 4 > IVR B
• rheumatoid arthritis > IVR 2 > IVR B
• severe chronic plaque psoriasis > IVR 5 > IVR A
• ulcerative colitis - adult and paediatric > IVR 6 > IVR B

aflibercept

Section 85 listed pharmaceutical benefit.

• diabetic macular oedema > IVR 3 > IVR C - Eyes
• retinal vein occlusion with macular oedema > IVR 3 > IVR C - Eyes
• subfoveal choroidal neovascularisation > IVR 3 > IVR C - Eyes
  due to:
  • age related macular degeneration
  • pathologic myopia

ambrisentan

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• pulmonary arterial hypertension > IVR 1 > IVR A

anifrolumab

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• systemic lupus erythematosus > IVR 2 > IVR B

armodafinil

Section 85 listed pharmaceutical benefit.

• narcolepsy > IVR 2 > IVR B

asciminib

Section 85 listed pharmaceutical benefit.

• chronic myeloid leukaemia > IVR 5 > IVR A

avatrombopag

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• idiopathic thrombocytopenic purpura > IVR 4 > IVR B

azacitidine

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• acute myeloid leukaemia > IVR 5 > IVR A
• chronic myelomonocytic leukaemia > IVR 5 > IVR A
• myelodysplastic syndrome > IVR 5 > IVR A

baricitinib

Section 85 listed pharmaceutical benefit.

• rheumatoid arthritis > IVR 2 > IVR B

benralizumab

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• severe asthma - adult and adolescent > IVR 1 > IVR A

bimekizumab

Section 85 listed pharmaceutical benefit.

• ankylosing spondylitis > IVR 2 > IVR B
• hidradenitis suppurativa > IVR 5 > IVR A
• non-radiographic axial spondyloarthritis > IVR 2 > IVR B
• psoriatic arthritis > IVR 4 > IVR B
• severe chronic plaque psoriasis - adult > IVR 5 > IVR A

blinatumomab

Section 100 - Efficient funding of chemotherapy arrangements.

• acute lymphoblastic leukaemia > IVR 5 > IVR A

bosentan

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• pulmonary arterial hypertension > IVR 1 > IVR A

brentuximab vedotin

Section 100 - Efficient funding of
chemotherapy arrangements.

• CD30 positive systemic anaplastic large cell lymphoma > IVR 5 > IVR A
• cutaneous T-cell lymphoma > IVR 5 > IVR A
• peripheral T-cell lymphoma > IVR 5 > IVR A
• relapsed or refractory Hodgkin lymphoma > IVR 5 > IVR A
• stage III or IV CD30 positive Hodgkin lymphoma > IVR 5 > IVR A

brolucizumab

Section 85 listed pharmaceutical benefit.

• age related macular degeneration > IVR 3 > IVR C - Eyes

burosumab

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• X-linked hypophosphataemia > IVR 1 > IVR A
• tumour induced osteomalacia > IVR 1 > IVR A

certolizumab pegol

Section 85 listed pharmaceutical benefit.

• ankylosing spondylitis > IVR 2 > IVR B
• non-radiographic axial spondyloarthritis > IVR 2 > IVR B
• psoriatic arthritis > IVR 4 > IVR B
• rheumatoid arthritis > IVR 2 > IVR B

crizotinib

Section 85 listed pharmaceutical benefit.

• Stage IIIB or Stage IV non-small-cell lung cancer > IVR 5 > IVR A

daratumumab

Section 85 and Section 100 - Efficient funding of
chemotherapy arrangements.

• untreated multiple myeloma > IVR 1 > IVR A
• Systemic light chain amyloidosis (AL) > General PBS listed
• Relapsed/refractory multiple myeloma (MM)> General PBS listed

dasatinib

Section 85 listed pharmaceutical benefit.

• acute lymphoblastic leukaemia > IVR 5 > IVR A
• chronic myeloid leukaemia > IVR 5 > IVR A

daunorubicin+cytarabine

Section 100 - Efficient funding of chemotherapy arrangements.

• acute myeloid leukaemia > IVR 5 > IVR A

decitabine+cedazuridine

Section 85 listed pharmaceutical benefit.

• Acute myeloid leukaemia (AML) > General PBS listed
• Chronic myelomonocytic leukaemia (CMML) > General PBS listed
• Myelodysplastic syndrome (MDS) > General PBS listed

dexamethasone implant

Section 85 listed pharmaceutical benefit.

• diabetic macular oedema > IVR 3 > IVR C - Eyes
• retinal vein occlusion with macular oedema > IVR 3 > IVR C - Eyes
• Posterior segment uveitis > General PBS listed

difelikefalin

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• chronic kidney disease-associated pruritus > IVR 4 > IVR B

dupilumab

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• severe asthma - adult and adolescent > IVR 1 > IVR A
• Chronic severe atopic dermatitis > General PBS listed

eculizumab

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• atypical haemolytic uraemic syndrome > IVR 1 > IVR A
• paroxysmal nocturnal haemoglobinuria > IVR 1 > IVR A

eflornithine

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• high-risk neuroblastoma > IVR 1 > IVR A

elexacaftor+tezacaftor+ivacaftor

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• cystic fibrosis > IVR 1 > IVR A

elotuzumab

Section 100 - Efficient funding of chemotherapy arrangements.

• multiple myeloma > IVR 1 > IVR A

elranatamab

Section 85 and Section 100 - Efficient funding of
chemotherapy arrangements.

• Relapsed/refractory multiple myeloma (MM) > General PBS listed

eltrombopag

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• idiopathic thrombocytopenic purpura > IVR 4 > IVR B
• severe aplastic anaemia > IVR 4 > IVR B

entrectinib

Section 85 listed pharmaceutical benefit.

• Stage IIIB or Stage IV non-small-cell lung cancer > IVR 5 > IVR A

epoprostenol

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• pulmonary arterial hypertension > IVR 1 > IVR A

etanercept

Section 85 and Section 100 listed
pharmaceutical benefit.

Public and private hospital authority required -
(Section 100 only).

• ankylosing spondylitis > IVR 2 > IVR B
• juvenile idiopathic arthritis > IVR 2 > IVR B
• psoriatic arthritis > IVR 4 > IVR B
• rheumatoid arthritis > IVR 2 > IVR B
• severe chronic plaque psoriasis - adult and paediatric > IVR 5 > IVR A

etrasimod

Section 85 listed pharmaceutical benefit.

• ulcerative colitis > IVR 6 > IVR B

faricimab

Section 85 listed pharmaceutical benefit.

• retinal vein occlusion with macular oedema > IVR 3 > IVR C - Eyes
• diabetic macular oedema > IVR 3 > IVR C - Eyes
• subfoveal choroidal neovascularisation > IVR 3 > IVR C - Eyes
  • due to age related macular degeneration

fedratinib

Section 85 listed pharmaceutical benefit.

• Myelofibrosis (MF) > General PBS listed

garadacimab

Section 85 listed pharmaceutical benefit.

• hereditary angioedema Types 1 or 2 > IVR 1 > IVR A

givosiran

Section 85 listed pharmaceutical benefit.

• chronic treatment of acute hepatic porphyria > IVR 4 > IVR B

golimumab

Section 85 listed pharmaceutical benefit.

• ankylosing spondylitis > IVR 2 > IVR B
• non-radiographic axial spondyloarthritis > IVR 2 > IVR B
• psoriatic arthritis > IVR 4 > IVR B
• rheumatoid arthritis > IVR 2 > IVR B
• ulcerative colitis - adult > IVR 6 > IVR B

guselkumab

Section 85 listed pharmaceutical benefit.

• psoriatic arthritis > IVR 4 > IVR B
• severe chronic plaque psoriasis - adult > IVR 5 > IVR A

idelalisib

Section 85 listed pharmaceutical benefit.

• Chronic lymphocytic leukaemia (CLL) > General PBS listed
• Small lymphocytic lymphoma (SLL) > General PBS listed
• Refractory follicular B-cell non-Hodgkin's lymphoma (Follicular Lymph) > General PBS listed

iloprost

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• pulmonary arterial hypertension > IVR 1 > IVR A

imatinib

Section 85 listed
pharmaceutical benefit.

• acute lymphoblastic leukaemia > IVR 5 > IVR A
• chronic myeloid leukaemia > IVR 5 > IVR A
• gastrointestinal stromal tumour > IVR 5 > IVR A
• Aggressive systemic mastocytosis with eosinophilia (ASM) > General PBS listed
• Chronic eosinophilic leukaemia or Hypereosinophilic syndrome (CEL/HES) > General PBS listed
• Dermatofibrosarcoma protuberans (DFSP) > General PBS listed
• Myelodysplastic or myeloproliferative disorder (MDP/MPD) > General PBS listed

infliximab

Section 85 and Section 100 listed
pharmaceutical benefit.

Public and private hospital authority required -
(Section 100 only).

• ankylosing spondylitis > IVR 2 > IVR B
• Crohn's disease - adult and paediatric (Section 100 only) > IVR 6 > IVR B
• fistulising Crohn's disease > IVR 6 > IVR B
• psoriatic arthritis > IVR 4 > IVR B
• rheumatoid arthritis > IVR 2 > IVR B
• severe chronic plaque psoriasis > IVR 5 > IVR A
• ulcerative colitis - adult and paediatric (Section 100 only) > IVR 6 > IVR B

inotuzumab ozogamicin

Section 100 - Efficient funding of chemotherapy arrangements

• acute lymphoblastic leukaemia > IVR 5 > IVR A

iptacopan

Section 85 listed pharmaceutical benefit.

• paroxysmal nocturnal haemoglobinuria > IVR 1 > IVR A

ivacaftor

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• cystic fibrosis > IVR 1 > IVR A

ixekizumab

Section 85 listed pharmaceutical benefit.

• ankylosing spondylitis > IVR 2 > IVR B
• psoriatic arthritis > IVR 4 > IVR B
• severe chronic plaque psoriasis > IVR 5 > IVR A

lanadelumab

Section 85 listed pharmaceutical benefit.

• hereditary angioedema type 1 or 2 > IVR 1 > IVR A

lapatinib

Section 85 listed pharmaceutical benefit.

• metastatic breast cancer > IVR 1 > IVR A

larotrectinib

Section 85 listed pharmaceutical benefit.

• solid tumours with confirmed neurotrophic tropomyosin receptor kinase (NTRK) gene fusion > IVR 5 > IVR A

lenalidomide

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• multiple myeloma > IVR 1 > IVR A
• myelodysplastic syndrome > IVR 5 > IVR A
• relapsed or refractory follicular lymphoma > IVR 5 > IVR A

lumacaftor+ivacaftor

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• cystic fibrosis > IVR 1 > IVR A

lumasiran

Section 85 listed pharmaceutical benefit.

Public and private hospital authority required.

• primary hyperoxaluria type 1 > IVR 4 > IVR B

macitentan

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• pulmonary arterial hypertension > IVR 1 > IVR A

macitentan+tadalafil

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• pulmonary arterial hypertension > IVR 1 > IVR A

mavacamten

Section 85 listed pharmaceutical benefit.

• symptomatic obstructive hypertrophic cardiomyopathy > IVR 1 > IVR A

mecasermin

Section 100 listed
pharmaceutical benefit.

• severe growth failure with primary insulin-like growth factor-1 deficiency > IVR 4 > IVR B

mepolizumab

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• severe asthma - adult and adolescent > IVR 1 > IVR A
• chronic rhinosinusitis with nasal polyps > IVR 1 > IVR A

midostaurin

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• acute myeloid leukaemia > IVR 5 > IVR A

migalastat

Section 85 listed pharmaceutical benefit.

• Fabry disease > IVR 2 > IVR B

modafinil

Section 85 listed pharmaceutical benefit.

• narcolepsy > IVR 2 > IVR B

mogamulizumab

Section 100 - Efficient funding of chemotherapy arrangements.

• cutaneous T-cell lymphoma > IVR 5 > IVR A

momelotinib

Section 85 listed pharmaceutical benefit.

• Myelofibrosis (MF) > General PBS listed

nilotinib

Section 85 listed pharmaceutical benefit.

• chronic myeloid leukaemia > IVR 5 > IVR A

nintedanib

Section 85 listed pharmaceutical benefit.

• idiopathic pulmonary fibrosis > IVR 1 > IVR A
• progressive fibrosing interstitial lung disease > IVR 1 > IVR A

nitisinone

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• hereditary tyrosinaemia type 1 > IVR 4 > IVR B

nusinersen

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• spinal muscular atrophy > IVR 2 > IVR B

odevixibat

Section 85 listed pharmaceutical benefit.

• progressive familial intrahepatic cholestasis > IVR 4 > IVR B

omalizumab

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• severe asthma > IVR 1 > IVR A
• chronic spontaneous urticaria > IVR 4 > IVR B

onasemnogene abeparvovec

Section 100 listed pharmaceutical benefit.

Public hospital authority required.

• spinal muscular atrophy > IVR 2 > IVR B

ozanimod

Section 85 listed pharmaceutical benefit.

• ulcerative colitis - adult > IVR 6 > IVR B

palovarotene

Section 85 listed pharmaceutical benefit.

• fibrodysplasia ossificans progressiva > IVR 2 > IVR B

pasireotide

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• acromegaly > IVR 1 > IVR A

pegcetacoplan

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• paroxysmal nocturnal haemoglobinuria > IVR 1 > IVR A

pegvisomant

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• acromegaly > IVR 1 > IVR A

pegunigalsidase alfa

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• Fabry disease > IVR 2 > IVR B

pembrolizumab

Section 100 - Efficient funding of
chemotherapy arrangements.

• Colorectal cancer > General PBS listed
• Hodgkin lymphoma (HL) > General PBS listed
• Malignant melanoma > General PBS listed
• Non-Small cell lung cancer (NSCLC) > General PBS listed
• Primary mediastinal B-cell lymphoma (PMBCL) > General PBS listed
• Squamous cell carcinoma > General PBS listed
• Urothelial cancer > General PBS listed

pertuzumab

Section 100 - Efficient funding of
chemotherapy arrangements.

• metastatic breast cancer > IVR 1 > IVR A
• early human epidermal growth factor receptor 2 positive breast cancer > IVR 1 > IVR A

pirfenidone

Section 85 listed pharmaceutical benefit.

• idiopathic pulmonary fibrosis > IVR 1 > IVR A

polylactic acid

Section 85 listed pharmaceutical benefit.

• severe facial lipoatrophy > IVR 4 > IVR B

pomalidomide

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• multiple myeloma > IVR 1 > IVR A

ponatinib

Section 85 listed pharmaceutical benefit.

• acute lymphoblastic leukaemia > IVR 5 > IVR A
• chronic myeloid leukaemia > IVR 5 > IVR A

ranibizumab

Section 85 listed pharmaceutical benefit.

• proliferative diabetic retinopathy and/or diabetic macular oedema > IVR 3 > IVR C - Eyes
• retinal vein occlusion with macular oedema > IVR 3 > IVR C - Eyes
• subfoveal choroidal neovascularisation > IVR 3 > IVR C - Eyes
  due to:
  • age related macular degeneration
  • pathologic myopia
  • other causes

ravulizumab

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• atypical haemolytic uraemic syndrome > IVR 1 > IVR A
• generalised myasthenia gravis > IVR 1 > IVR A
• neuromyelitis optica spectrum disorder > IVR 1 > IVR A
• paroxysmal nocturnal haemoglobinuria > IVR 1 > IVR A

repotrectinib

Section 85 listed pharmaceutical benefit.

• Stage IIIB or Stage IV non-small-cell lung cancer > IVR 5 > IVR A

riociguat

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• chronic thromboembolic pulmonary hypertension > IVR 1 > IVR A
• pulmonary arterial hypertension > IVR 1 > IVR A

ripretinib

Section 85 listed pharmaceutical benefit.

• gastrointestinal stromal tumour > IVR 5 > IVR A

risankizumab

Section 85 listed pharmaceutical benefit.

• severe chronic plaque psoriasis - adult > IVR 5 > IVR A
• severe psoriatic arthritis > IVR 4 > IVR B

risdiplam

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• spinal muscular atrophy > IVR 2 > IVR B

rituximab

Section 100 - Highly specialised drug (HSD) or Efficient funding of
chemotherapy (EFC) arrangements.

Public and private hospital authority required -
(HSD only).

• Conditions other than oncology > IVR 2 & 4 > IVR B
• Oncology indications > General PBS listed

romiplostim

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• idiopathic thrombocytopenic purpura > IVR 4 > IVR B

rozanolixizumab

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• generalised myasthenia gravis > IVR 1 > IVR A

ruxolitinib

Section 85 listed pharmaceutical benefit.

• polycythemia vera > IVR 5 > IVR A
• Acute or chronic graft versus host disease (GVHD) > General PBS listed
• Myelofibrosis (MF) > General PBS listed

secukinumab

Section 85 listed pharmaceutical benefit.

• ankylosing spondylitis > IVR 2 > IVR B
• hidradenitis suppurativa > IVR 5 > IVR A
• non-radiographic axial spondyloarthritis > IVR 2 > IVR B
• psoriatic arthritis > IVR 4 > IVR B
• severe chronic plaque psoriasis > IVR 5 > IVR A

selexipag

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• pulmonary arterial hypertension > IVR 1 > IVR A

selinexor

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• Multiple myeloma (MM) > General PBS listed

selumetinib

Section 85 listed pharmaceutical benefit.

• neurofibromatosis type 1 > IVR 5 > IVR A

sildenafil

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• pulmonary arterial hypertension > IVR 1 > IVR A

somapacitan

Section 100 listed pharmaceutical benefit.

• growth hormone deficiency - paediatric > IVR 4 > IVR B

somatrogon

Section 100 listed pharmaceutical benefit.

• growth hormone deficiency - paediatric > IVR 4 > IVR B

somatropin

Section 100 listed pharmaceutical benefit.

• growth hormone deficiency - childhood or late onset > IVR 4 > IVR B
• growth hormone deficiency - paediatric > IVR 4 > IVR B

sonidegib

Section 85 listed pharmaceutical benefit.

• basal cell carcinoma > IVR 1 > IVR A

sunitinib

Section 85 listed pharmaceutical benefit.

• malignant gastrointestinal stromal tumour > IVR 5 > IVR A
• Pancreatic neuroendocrine tumour (pNET) > General PBS listed
• Renal cell carcinoma (RCC) > General PBS listed

tadalafil

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• pulmonary arterial hypertension > IVR 1 > IVR A

tafamidis

Section 85 listed pharmaceutical benefit.

• transthyretin amyloid cardiomyopathy > IVR 1 > IVR A

tafasitamab

Section 100 - Efficient funding of chemotherapy arrangements.

• relapsed or refractory follicular lymphoma > IVR 5 > IVR A

teduglutide

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• short bowel syndrome with intestinal failure > IVR 4 > IVR B

tezacaftor+ivacaftor

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• cystic fibrosis > IVR 1 > IVR A

tezepelumab

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• severe asthma - adult and adolescent > IVR 1 > IVR A

tildrakizumab

Section 85 listed pharmaceutical benefit.

• severe chronic plaque psoriasis - adult > IVR 5 > IVR A

tocilizumab

Section 85 and Section 100 listed pharmaceutical benefit.

Public and private hospital authority required -
(Section 100 listing only).

• juvenile idiopathic arthritis > IVR 2 > IVR B
• giant cell arteritis > IVR 2 > IVR B
• rheumatoid arthritis > IVR 2 > IVR B
• systemic juvenile idiopathic arthritis > IVR 2 > IVR B

tofacitinib

Section 85 listed pharmaceutical benefit.

• ankylosing spondylitis > IVR 2 > IVR B
• juvenile idiopathic arthritis > IVR 2 > IVR B
• psoriatic arthritis > IVR 4 > IVR B
• rheumatoid arthritis > IVR 2 > IVR B
• ulcerative colitis - adult > IVR 6 > IVR B

trastuzumab

Section 85 and Section 100 -
Efficient funding of
chemotherapy
arrangements.

• early human epidermal growth factor receptor 2 positive breast cancer > IVR 1 > IVR A
• gastric cancer > IVR 1 > IVR A
• metastatic breast cancer > IVR 1 > IVR A

trastuzumab emtansine

Section 100 -
Efficient funding of
chemotherapy
arrangements.

• early human epidermal growth factor receptor 2 positive breast cancer > IVR 1 > IVR A
• metastatic breast cancer > IVR 1 > IVR A

upadacitinib

Section 85 listed pharmaceutical benefit.

• ankylosing spondylitis > IVR 2 > IVR B
• Crohn's disease - adult > IVR 6 > IVR B
• non-radiographic axial spondyloarthritis > IVR 2 > IVR B
• psoriatic arthritis > IVR 4 > IVR B
• rheumatoid arthritis > IVR 2 > IVR B
• ulcerative colitis - adult > IVR 6 > IVR B
• Chronic severe atopic dermatitis > General PBS listed

ustekinumab

Section 85 and Section 100 listed pharmaceutical benefit.

Public and private hospital authority required -
(Section 100 only).

• Crohn's disease - adult > IVR 6 > IVR B
• fistulising Crohn's disease > IVR 6 > IVR B
• psoriatic arthritis > IVR 4 > IVR B
• severe chronic plaque psoriasis > IVR 5 > IVR A
• ulcerative colitis - adult > IVR 6 > IVR B

vanzacaftor+tezacaftor+deutivacaftor

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• cystic fibrosis > IVR 1 > IVR A

vedolizumab

Section 85 and Section 100 listed pharmaceutical benefit.

Public and private hospital authority required -
(Section 100 only)

• Crohn's disease - adult > IVR 6 > IVR B
• chronic pouchitis > IVR 6 > IVR B
• ulcerative colitis - adult > IVR 6 > IVR B

venetoclax+azacitidine

Section 85 (venetoclax) and Section 100 (azacitidine)
listed pharmaceutical benefit.

Public and private hospital authority required -
(Section 100 azacitidine only)

• Acute myeloid leukaemia (AML) > IVR 5 > IVR A

vismodegib

Section 85 listed pharmaceutical benefit.

• basal cell carcinoma > IVR 1 > IVR A

vorinostat

Section 85 listed pharmaceutical benefit.

• cutaneous T-cell lymphoma > IVR 5 > IVR A

vutrisiran

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• hereditary transthyretin amyloidosis > IVR 1 > IVR A

zilucoplan

Section 100 listed pharmaceutical benefit.

Public and private hospital authority required.

• generalised myasthenia gravis > IVR 1 > IVR A